About Retatrutide
Retatrutide is a next generation triple agonist peptide currently being researched for weight management, metabolic health and appetite regulation. Unlike traditional GLP-1 compounds, Retatrutide targets three separate hormone receptors including GLP-1, GIP and glucagon receptors.
This triple action approach is being researched for its potential to:
- Support significant fat loss research
- Help reduce appetite and cravings in research models
- Improve insulin sensitivity
- Increase energy expenditure and metabolic activity
- Assist with blood sugar regulation research
- Support long term body composition research
Retatrutide has become one of the most talked about research peptides due to its potential strength and advanced mechanism compared to earlier GLP-1 compounds.
Retatrutide vs Semaglutide vs Tirzepatide
| Feature |
Retatrutide |
Tirzepatide |
Semaglutide |
| Receptor Targets | GLP-1 + GIP + Glucagon | GLP-1 + GIP | GLP-1 only |
| Generation | Triple agonist | Dual agonist | Single agonist |
| Research Focus | Metabolic + energy expenditure | Metabolic + incretin | Incretin + appetite |
| Available Sizes | 5–60mg | 2–100mg | 5–30mg |
Research Use Only. Not a medicine, not a supplement, not approved for human or animal use. No medical advice or dosage guidance provided.